Koosan@ sorry as an investor my objective is invest in companies to generate total returns (capital growth+ Dividend income) from my investments! I am not investing in for charitable cause. There is no other way to judge successful investment than capital,growth! Absurd statement to say don’t just judge company based on their share performance. I am not too worried about short term underperformance but we are talking about underperformance since 2011. Blaming the exchange rate is also ridiculous! It all to do with governance I am afraid.
Dumb far.k. Wasting my time with these kind of people.
Please la @Diam88, my RPT articles and posts are in response to @tkkiong's posts of bringing up past RPTs. Even @Riaz constantly brought it up. The truth is often hard to swallow, history lessons often forgotten fast. I have already publicly declared here that i have no position in this stock. Being a shareholder of Taurx, my interests are aligned with GenB. Only amateurs think that posting here will move the stock price. I made several millions in profit from trading this stock from 2020 to 2023 with trade success rate between 80 to 90%. I dont have to resort to low end cheap tactics to scare people here, hoping to buy cheap. Or do nonstop yapping bullish things here hoping to sell high. Im confident of my own trading skills. I do hope that all of you huat from investing / trading this stock.
Posted by AngTayKor > 2024-01-27 02:13 | Report Abuse
Posted by Kikilala3188 > | Report Abuse Taurx when will it be announcing? Especially U.K. FDA approval ---------------
ATK: UK MHRA's final decision on CA is unlikely to be within 2024. We still have to file in more submissions which will take abt 5 to 6 months to complete it, followed by another 6 to 9 months for the regulator's final decision.
FDA delayed our Type C meeting request (supposed to be end Jan, before Taurx AGM on 6 Feb @6pm). We are not even sure if FDA will agree to consider HMTM using the Accelerated Approval pathway. If yes, I think FDA's final decision for AA will probably be at least 1.5yrs away. --------------
Posted by AngTayKor > 2 weeks ago | Report Abuse
Posted by neohts > | Report Abuse Ask TauRX status, when can get approval? ---------
ATK: UAE CA end of 2024. UK, USA, EU CAs 2025 liow.
--------------- Posted by Balian de Ibelin > 4 hours ago | Report Abuse Taurx decision anytime soon. This is a gambling buy for the Shoot Up!! Which other counter in BURSA right now today can give you this Gambling Buy? All in, Sell all your Birkin bags to buy Genting. --------------
Already posted the timeline here since Jan 2024. Things will change, usually delays and not earlier. Currently, my anticipated FDA AA decision is somewhere late 2025.
@Koosan, no need to be rude! We are investors wanting the company to do well and generate returns to the shareholders… nothing else! Sometimes you have to accept the truth no matter how bitter. I remain invested because I want Genting to move away from the past and get investors confidence! Confidence current and future shareholders os important if we want share price to rise and provide returns to shareholders who are patiently waiting!
No doubt Genting is trading at considerable discount and for it narrow we need to see more shareholder focussed action so that we can all enjoy the returns
Normal punters entering LKT's casino de bursa stocks have little chance to outsmart the whale n make some trading profit. If you are an experienced, sharp n cunning trader, you can steal some crumbs from the whale's lunch, else you become the whale's lunch. --------------
Stock trading is inherently a risky endeavor. Most amateurs will lose money. You need to be the top 10% to make money consistently. The top 2% are the ones making most of the money.
Kedah recorded the highest value of approved investments (RM31.3 billion), followed by Kuala Lumpur (RM21.5 billion), Selangor (RM12.4 billion), Sarawak (RM4.2 billion), and Johor (RM4.1 billion).
MITI minister Tengku Datuk Seri Zafrul Abdul Aziz said that approved investments of almost RM84 billion for Q12024 reflect how Malaysia has earned investors' trust.
Despite the significant discussion around mega investments in Johor, it is currently trailing behind Sarawak.
Certainly! Genting Berhad, a prominent Malaysian conglomerate, serves as an investment holding and management company. Founded in 1965 by the late Tan Sri Lim Goh Tong, the Genting Group embarked on a visionary journey to create a mountaintop resort in Malaysia. Let’s delve into the concept of Conglomerate Discount and its relevance to Genting Berhad.
Conglomerate Discount refers to a situation where the market values a diversified conglomerate at a lower price than the sum of its individual parts (i.e., the value of its subsidiary companies). Essentially, the conglomerate’s overall worth appears discounted due to its diverse business portfolio.
In the case of Genting Berhad, analysts at financial services group Nomura have observed significant market cap discounts. Here are the key points:
1)Market Cap Discount: Genting’s current market cap seems to discount all non-Singapore assets. It has been trading below the value of its 52% stake in Genting Singapore. Additionally, the market appears to disregard the value of other businesses under Genting, including listed subsidiaries (e.g., its 49% stake in Genting Malaysia and 55% stake in Genting Plantations) and unlisted businesses (such as Resorts World Las Vegas, energy, and utilities).
2)Estimated Contribution: These discounted, “free” businesses are estimated to contribute approximately 62% of Genting’s FY23F EBITDA.
3)Discount Levels: Genting is trading at a 66% discount to the value of listed subsidiaries. It is also trading at a 47% discount to the value of both listed and unlisted subsidiaries.
4)Unjustifiably Wide Discount: The holding company’s RNAV (Revalued Net Asset Value) discount is considered unjustifiably wide. Analysts believe this discount will narrow as macro risks ease and tourism recovery continues in FY23F/24F.
5)Upgraded Rating: Nomura has upgraded Genting Berhad to a “Buy” rating, raising revenue and EBITDA estimates for Genting Malaysia. Although profit estimates were adjusted due to higher depreciation and interest costs, the overall outlook remains positive.
In summary, while Genting Berhad faces the Conglomerate Discount phenomenon, analysts believe that the current discount is unwarranted and may narrow over time. As macroeconomic conditions improve and tourism rebounds, the market’s perception of Genting’s diversified assets could change.
Remember that investing decisions should consider various factors, including risk tolerance, financial goals, and market dynamics. Always seek professional financial advice before making investment choices.
Arrivals totalled 5.8 million tourists in January to March, an increase of 33% when compared to the same period last year, but lower than the 6.82 million arrivals needed for each quarter to achieve the full-year target for 2024, TA Securities said in a note. The number of tourists was also about 8% lower than the average in the same quarter before the Covid-19 pandemic, it noted.
“There is ample room for Malaysia to maximise benefits from selected countries to achieve optimal traffic and revenue,” TA Securities said. 陈剑大師錯了, 1) 旅游业还在复苏中.. 2)不是因为旅游业复苏...actually 是阿公pushed up share price to facilitate the privatization of MAHB la...
Genting’s Oil Kasuri operates the Asap-Kido Merah gas field’s concession in Indonesia’s West Papua province that was secured back in 2008.
“We deem that Genting’s Oil Kasuri will supply the feed natural gas to this FLNG project operated by PTLNG, where natural gas can be extracted from the reservoir and converted into 1.2 mpta LNG for exports.
“Assuming pre-pandemic’s five-year average LNG price of US$9 and Genting’s FLNG is able to operate at its capacity of 1.2 mpta, potential revenue accretion for Genting is as high as RM2.64bil annually (8% of our 2026-2027 revenue forecasts),” UOB Kay Hian said.
Posted by AngTayKor > 2023-07-04 12:41 | Report Abuse
........... HMTM works so beautifully.
1. HMTM already proven in phase 3 it can totally halt AD cognitive decline + 20% improvement in cognitive scores VS Lecanemab's 27% slowdown in decline but continue to decline at 73%.
2. HMTM has minimal side effects VS high brain bleeding chances including numerous death cases for Lecanemab
3. HMTM slows down brain atrophy (shrinkage) VS Lecanemab's accelerated brain shrinkage. This is definitely going in the wrong direction of how a good AD drug shd perform. ATK is expecting major efficacy and safety fiascos for Lecanemab in future.
4. HMTM at USD10k/ year VS Lecanemab's USD26k/yr treatment cost.
5, HMTM orally taken drug twice a day at home VS Lecanemab's twice a month infusion (like kidney dialysis) in hospital with multiple brain scans required for constant costly monitoring for ARIA. -----------------
Posted by AngTayKor > 2023-10-25 12:46 | Report Abuse
@TAUkay, some years ago Prof CW still thinking abt USD3K treatment cost. I shot back at him during AGM that nobody will pity us if we fail so we dont have to do subsidised treatment cost charity here. He better not say this price to any media and shoot our own foot. Low treatment cost = Low grand jackpot pricing. Me as a shareholder waiting for grand jackpot for years, so dont short change us. The USD10k figure was due to Medicare drug reimbursement issues. But whats the limit here? The sky is the limit for us. We dont need to do those numerous PET scans and MRI scans, bi-weekly 2 hr intravenous drug delivery, constant monitoring for ARIAs by neurologists, etc. All these can add up tens of thousands on top of amyloid drug cost. Its crazy to use them, just go back to the good old aricept that is much safer and works much better at 2% of these amyloid treatment cost la. Thanks to Aducanumab's USD56K initial pricing, rising tide lift all boats. USD10k treatment cost VS USD270k total economic cost per AD patient. I bet ICER will give us a drug treatment value of at least USD50K to 70K. HMTM can totally halt disease progression + reverse it. **************
The real cost of using lecanemab shd be somewhere close to USD50k yearly after including multiple PET and MRI scans, cost of bi-weekly intravenous deliveries followed by neuro consultations etc. For HMTM, there is no need for PET/MRI scans + more neuro consultations. Just take the blue pills go home and consume them yourself daily. If pricing HMTM at 50% discount (USD13k yearly) compared to lecanemab's USD26k yearly drug cost, is not doing justice to HMTM.
Posted by Balian de Ibelin > 1 minute ago | Report Abuse
Sometimes a Guaranteed 30 sen profits very short term from GenM is way better. Rather than a pie in sky from Genting.
Trouble free money in bag. --------------
@Balian, my Taurx position is sitting on USD30m profit as of now. Trouble free money in bag, Immediately Buy Immediately Huat. Every investor / trader must know very very clearly what they are doing.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Michaelchan2024
1,232 posts
Posted by Michaelchan2024 > 2024-06-24 11:02 | Report Abuse
No offence, don't throw eggs at me hor..